Table 5. Open in new tab Clinical...

	Gram-Positive Cocci Bacteremia (Excluding CoNS)	CoNS Bacteremia	Gram-Negative Rod Bacteremia
LOS
Hospital LOS	10.3 (6.2–18.2)	9.5 (5.9–20.1)	7.9 (6.1–13.6)	.567	7.2 (4.8–11.3)	5.5 (3.3–8.9)^a	4.5 (2.9–9.7)^a	.003	7.7 (4.4–15.0)	3.8 (3.1–7.0)^{a, b}	8.0 (4.2–14.1)	.008
Hospital LOS following culture collection	8.3 (5.9–11.0)	7.5 (5.1–14.0)	7.3 (5.7–11.2)	.813	6.1 (4.1–8.6)	4.8 (3.0–7.7)^a	4.2 (2.9–7.3)^a	.026	6.8 (4.4–10.5)	3.8 (3.0–6.9)^a	5.5 (4.0–10.8)	.014
ICU LOS	4.7 (2.0–10.7)	6.0 (1.6–9.4)	4.5 (3.1–6.7)	.866	2.0 (0.9–3.7)	2.6 (1.4–4.1)	2.1 (1.4–3.2)	.313	2.8 (1.6–6.5)	1.9 (1.4–5.0)	2.8 (1.6–4.0)	.864
ICU LOS following culture collection	3.5 (1.7–6.2)	3.0 (4.6–9.4)	4.7 (3.1–5.5)	.728	1.6 (0.9–3.5)	2.2 (1.3–4.0)	2.0 (1.0–2.9)	.606	2.7 (1.6–3.8)	1.9 (1.4–5.0)	2.8 (1.6–4.0)	.898
Optimal therapy
Achieved optimal therapy, No. (%)	51 (94.4)	43 (93.5)	36 (100.0)	.317	62 (78.5)	71 (94.7)^a	71 (93.4)^a	.002	42 (82.0)	28 (90.3)	31 (93.9)	.238
TTOT following culture collection	2.8 (1.9–3.4)	1.8 (0.8–2.8)^a	1.5 (1.1–1.9)^a	≤ .001	2.9 (0.5–3.5)	1.3 (0.0–2.3)^a	1.0 (0.0–2.0)^a	≤ .001	3.2 (2.2–3.9)	1.4 (0.5–2.0)^a	1.5 (1.0–2.1)^a	≤ .001
CDI within 90 d, No. (%)	2 (3.7)	1 (2.2)	3 (8.3)	.385	1 (1.3)	4 (5.3)	5 (6.6)	.237	2 (4.0)	3 (9.7)	4 (12.1)	.373
In-hospital transition to hospice care, No. (%)	4 (7.4)	7 (15.2)	2 (5.6)	.267	6 (7.6)	4 (5.3)	4 (5.3)	.788	2 (4.0)	4 (12.9)	2 (6.1)	.306
In-hospital mortality, No. (%)	5 (9.3)	7 (15.2)	2 (5.6)	.345	6 (7.6)	2 (2.7)	4 (5.3)	.390	4 (8.0)	2 (6.5)	4 (12.1)	.704
Antibiotic use
Total antibiotic use	8 (7–12)	9 (6–14)	8 (6–12)	.913	6 (4–9)	5 (2–7)	4 (3–7)	.060	8 (5–11)	5 (4–8)^a,b	6 (5–12)	.007
BGP	4 (2–7)	5 (2–9)	4 (2–7)	.845	4 (2–6)	3 (1–6)^a	2 (1–4)^a	.003	2 (0–4)	2 (1–3)	1 (0–4)	.719
Vancomycin	3 (2–6)	4 (2–9)	4 (2–7)	.997	5 (3–7)	3 (2–7)	3 (2–4)^a	.002	2 (1–4)	2 (1–3)	2 (1–6)	.438
BGN	4 (2–6)	4 (1–6)	3 (2–5)	.636	4 (1–7)	2 (0–7)	3 (0–5)^a	.046	7 (4–10)	4 (2–7)^a	5 (2–8)^a	.028
NBL	3 (0–8)	4 (0–6)	4 (1–7)	.749	0 (0–1)	0 (0–2)^a	0 (0–2)^a	.010	1 (0–4)	0 (0–2) ^b	3 (2–5)^a	.001

Gram-Positive Cocci Bacteremia (Excluding CoNS)

CoNS Bacteremia

Gram-Negative Rod Bacteremia

Outcome and Antibiotic Use

Historical (n = 54)

AXDX (n = 46)

AXDX + RTN (n = 36)

P Value

Historical (n = 79)

AXDX (n = 75)

AXDX + RTN (n = 76)

P Value

Historical (n = 50)

AXDX (n = 31)

AXDX + RTN (n = 33)

P Value

LOS

Hospital LOS

10.3 (6.2–18.2)

9.5 (5.9–20.1)

7.9 (6.1–13.6)

.567

7.2 (4.8–11.3)

5.5 (3.3–8.9)^a

4.5 (2.9–9.7)^a

.003

7.7 (4.4–15.0)

3.8 (3.1–7.0)^{a, b}

8.0 (4.2–14.1)

.008

Hospital LOS following culture collection

8.3 (5.9–11.0)

7.5 (5.1–14.0)

7.3 (5.7–11.2)

.813

6.1 (4.1–8.6)

4.8 (3.0–7.7)^a

4.2 (2.9–7.3)^a

.026

6.8 (4.4–10.5)

3.8 (3.0–6.9)^a

5.5 (4.0–10.8)

.014

ICU LOS

4.7 (2.0–10.7)

6.0 (1.6–9.4)

4.5 (3.1–6.7)

.866

2.0 (0.9–3.7)

2.6 (1.4–4.1)

2.1 (1.4–3.2)

.313

2.8 (1.6–6.5)

1.9 (1.4–5.0)

2.8 (1.6–4.0)

.864

ICU LOS following culture collection

3.5 (1.7–6.2)

3.0 (4.6–9.4)

4.7 (3.1–5.5)

.728

1.6 (0.9–3.5)

2.2 (1.3–4.0)

2.0 (1.0–2.9)

.606

2.7 (1.6–3.8)

1.9 (1.4–5.0)

2.8 (1.6–4.0)

.898

Optimal therapy

Achieved optimal therapy, No. (%)

51 (94.4)

43 (93.5)

36 (100.0)

.317

62 (78.5)

71 (94.7)^a

71 (93.4)^a

.002

42 (82.0)

28 (90.3)

31 (93.9)

.238

TTOT following culture collection

2.8 (1.9–3.4)

1.8 (0.8–2.8)^a

1.5 (1.1–1.9)^a

≤ .001

2.9 (0.5–3.5)

1.3 (0.0–2.3)^a

1.0 (0.0–2.0)^a

≤ .001

3.2 (2.2–3.9)

1.4 (0.5–2.0)^a

1.5 (1.0–2.1)^a

≤ .001

CDI within 90 d, No. (%)

2 (3.7)

1 (2.2)

3 (8.3)

.385

1 (1.3)

4 (5.3)

5 (6.6)

.237

2 (4.0)

3 (9.7)

4 (12.1)

.373

In-hospital transition to hospice care, No. (%)

4 (7.4)

7 (15.2)

2 (5.6)

.267

6 (7.6)

4 (5.3)

.788

2 (4.0)

4 (12.9)

2 (6.1)

.306

In-hospital mortality, No. (%)

5 (9.3)

7 (15.2)

2 (5.6)

.345

6 (7.6)

2 (2.7)

4 (5.3)

.390

4 (8.0)

2 (6.5)

4 (12.1)

.704

Antibiotic use

Total antibiotic use

8 (7–12)

9 (6–14)

8 (6–12)

.913

6 (4–9)

5 (2–7)

4 (3–7)

.060

8 (5–11)

5 (4–8)^a,b

6 (5–12)

.007

BGP

4 (2–7)

5 (2–9)

4 (2–7)

.845

4 (2–6)

3 (1–6)^a

2 (1–4)^a

.003

2 (0–4)

2 (1–3)

1 (0–4)

.719

Vancomycin

3 (2–6)

4 (2–9)

4 (2–7)

.997

5 (3–7)

3 (2–7)

3 (2–4)^a

.002

2 (1–4)

2 (1–3)

2 (1–6)

.438

BGN

4 (2–6)

4 (1–6)

3 (2–5)

.636

4 (1–7)

2 (0–7)

3 (0–5)^a

.046

7 (4–10)

4 (2–7)^a

5 (2–8)^a

.028

NBL

3 (0–8)

4 (0–6)

4 (1–7)

.749

0 (0–1)

0 (0–2)^a

.010

1 (0–4)

0 (0–2) ^b

3 (2–5)^a

.001

	Gram-Positive Cocci Bacteremia (Excluding CoNS)	CoNS Bacteremia	Gram-Negative Rod Bacteremia
LOS
Hospital LOS	10.3 (6.2–18.2)	9.5 (5.9–20.1)	7.9 (6.1–13.6)	.567	7.2 (4.8–11.3)	5.5 (3.3–8.9)^a	4.5 (2.9–9.7)^a	.003	7.7 (4.4–15.0)	3.8 (3.1–7.0)^{a, b}	8.0 (4.2–14.1)	.008
Hospital LOS following culture collection	8.3 (5.9–11.0)	7.5 (5.1–14.0)	7.3 (5.7–11.2)	.813	6.1 (4.1–8.6)	4.8 (3.0–7.7)^a	4.2 (2.9–7.3)^a	.026	6.8 (4.4–10.5)	3.8 (3.0–6.9)^a	5.5 (4.0–10.8)	.014
ICU LOS	4.7 (2.0–10.7)	6.0 (1.6–9.4)	4.5 (3.1–6.7)	.866	2.0 (0.9–3.7)	2.6 (1.4–4.1)	2.1 (1.4–3.2)	.313	2.8 (1.6–6.5)	1.9 (1.4–5.0)	2.8 (1.6–4.0)	.864
ICU LOS following culture collection	3.5 (1.7–6.2)	3.0 (4.6–9.4)	4.7 (3.1–5.5)	.728	1.6 (0.9–3.5)	2.2 (1.3–4.0)	2.0 (1.0–2.9)	.606	2.7 (1.6–3.8)	1.9 (1.4–5.0)	2.8 (1.6–4.0)	.898
Optimal therapy
Achieved optimal therapy, No. (%)	51 (94.4)	43 (93.5)	36 (100.0)	.317	62 (78.5)	71 (94.7)^a	71 (93.4)^a	.002	42 (82.0)	28 (90.3)	31 (93.9)	.238
TTOT following culture collection	2.8 (1.9–3.4)	1.8 (0.8–2.8)^a	1.5 (1.1–1.9)^a	≤ .001	2.9 (0.5–3.5)	1.3 (0.0–2.3)^a	1.0 (0.0–2.0)^a	≤ .001	3.2 (2.2–3.9)	1.4 (0.5–2.0)^a	1.5 (1.0–2.1)^a	≤ .001
CDI within 90 d, No. (%)	2 (3.7)	1 (2.2)	3 (8.3)	.385	1 (1.3)	4 (5.3)	5 (6.6)	.237	2 (4.0)	3 (9.7)	4 (12.1)	.373
In-hospital transition to hospice care, No. (%)	4 (7.4)	7 (15.2)	2 (5.6)	.267	6 (7.6)	4 (5.3)	4 (5.3)	.788	2 (4.0)	4 (12.9)	2 (6.1)	.306
In-hospital mortality, No. (%)	5 (9.3)	7 (15.2)	2 (5.6)	.345	6 (7.6)	2 (2.7)	4 (5.3)	.390	4 (8.0)	2 (6.5)	4 (12.1)	.704
Antibiotic use
Total antibiotic use	8 (7–12)	9 (6–14)	8 (6–12)	.913	6 (4–9)	5 (2–7)	4 (3–7)	.060	8 (5–11)	5 (4–8)^a,b	6 (5–12)	.007
BGP	4 (2–7)	5 (2–9)	4 (2–7)	.845	4 (2–6)	3 (1–6)^a	2 (1–4)^a	.003	2 (0–4)	2 (1–3)	1 (0–4)	.719
Vancomycin	3 (2–6)	4 (2–9)	4 (2–7)	.997	5 (3–7)	3 (2–7)	3 (2–4)^a	.002	2 (1–4)	2 (1–3)	2 (1–6)	.438
BGN	4 (2–6)	4 (1–6)	3 (2–5)	.636	4 (1–7)	2 (0–7)	3 (0–5)^a	.046	7 (4–10)	4 (2–7)^a	5 (2–8)^a	.028
NBL	3 (0–8)	4 (0–6)	4 (1–7)	.749	0 (0–1)	0 (0–2)^a	0 (0–2)^a	.010	1 (0–4)	0 (0–2) ^b	3 (2–5)^a	.001

Gram-Positive Cocci Bacteremia (Excluding CoNS)

CoNS Bacteremia

Gram-Negative Rod Bacteremia

Outcome and Antibiotic Use

Historical (n = 54)

AXDX (n = 46)

AXDX + RTN (n = 36)

P Value

Historical (n = 79)

AXDX (n = 75)

AXDX + RTN (n = 76)

P Value

Historical (n = 50)

AXDX (n = 31)

AXDX + RTN (n = 33)

P Value

LOS

Hospital LOS

10.3 (6.2–18.2)

9.5 (5.9–20.1)

7.9 (6.1–13.6)

.567

7.2 (4.8–11.3)

5.5 (3.3–8.9)^a

4.5 (2.9–9.7)^a

.003

7.7 (4.4–15.0)

3.8 (3.1–7.0)^{a, b}

8.0 (4.2–14.1)

.008

Hospital LOS following culture collection

8.3 (5.9–11.0)

7.5 (5.1–14.0)

7.3 (5.7–11.2)

.813

6.1 (4.1–8.6)

4.8 (3.0–7.7)^a

4.2 (2.9–7.3)^a

.026

6.8 (4.4–10.5)

3.8 (3.0–6.9)^a

5.5 (4.0–10.8)

.014

ICU LOS

4.7 (2.0–10.7)

6.0 (1.6–9.4)

4.5 (3.1–6.7)

.866

2.0 (0.9–3.7)

2.6 (1.4–4.1)

2.1 (1.4–3.2)

.313

2.8 (1.6–6.5)

1.9 (1.4–5.0)

2.8 (1.6–4.0)

.864

ICU LOS following culture collection

3.5 (1.7–6.2)

3.0 (4.6–9.4)

4.7 (3.1–5.5)

.728

1.6 (0.9–3.5)

2.2 (1.3–4.0)

2.0 (1.0–2.9)

.606

2.7 (1.6–3.8)

1.9 (1.4–5.0)

2.8 (1.6–4.0)

.898

Optimal therapy

Achieved optimal therapy, No. (%)

51 (94.4)

43 (93.5)

36 (100.0)

.317

62 (78.5)

71 (94.7)^a

71 (93.4)^a

.002

42 (82.0)

28 (90.3)

31 (93.9)

.238

TTOT following culture collection

2.8 (1.9–3.4)

1.8 (0.8–2.8)^a

1.5 (1.1–1.9)^a

≤ .001

2.9 (0.5–3.5)

1.3 (0.0–2.3)^a

1.0 (0.0–2.0)^a

≤ .001

3.2 (2.2–3.9)

1.4 (0.5–2.0)^a

1.5 (1.0–2.1)^a

≤ .001

CDI within 90 d, No. (%)

2 (3.7)

1 (2.2)

3 (8.3)

.385

1 (1.3)

4 (5.3)

5 (6.6)

.237

2 (4.0)

3 (9.7)

4 (12.1)

.373

In-hospital transition to hospice care, No. (%)

4 (7.4)

7 (15.2)

2 (5.6)

.267

6 (7.6)

4 (5.3)

.788

2 (4.0)

4 (12.9)

2 (6.1)

.306

In-hospital mortality, No. (%)

5 (9.3)

7 (15.2)

2 (5.6)

.345

6 (7.6)

2 (2.7)

4 (5.3)

.390

4 (8.0)

2 (6.5)

4 (12.1)

.704

Antibiotic use

Total antibiotic use

8 (7–12)

9 (6–14)

8 (6–12)

.913

6 (4–9)

5 (2–7)

4 (3–7)

.060

8 (5–11)

5 (4–8)^a,b

6 (5–12)

.007

BGP

4 (2–7)

5 (2–9)

4 (2–7)

.845

4 (2–6)

3 (1–6)^a

2 (1–4)^a

.003

2 (0–4)

2 (1–3)

1 (0–4)

.719

Vancomycin

3 (2–6)

4 (2–9)

4 (2–7)

.997

5 (3–7)

3 (2–7)

3 (2–4)^a

.002

2 (1–4)

2 (1–3)

2 (1–6)

.438

BGN

4 (2–6)

4 (1–6)

3 (2–5)

.636

4 (1–7)

2 (0–7)

3 (0–5)^a

.046

7 (4–10)

4 (2–7)^a

5 (2–8)^a

.028

NBL

3 (0–8)

4 (0–6)

4 (1–7)

.749

0 (0–1)

0 (0–2)^a

.010

1 (0–4)

0 (0–2) ^b

3 (2–5)^a

.001

Table 5.

Open in new tab

Clinical Outcomes and Antibiotic Utilization in Pathogen Subgroups

	Gram-Positive Cocci Bacteremia (Excluding CoNS)				CoNS Bacteremia				Gram-Negative Rod Bacteremia
Outcome and Antibiotic Use	Historical (n = 54)	AXDX (n = 46)	AXDX + RTN (n = 36)	P Value	Historical (n = 79)	AXDX (n = 75)	AXDX + RTN (n = 76)	P Value	Historical (n = 50)	AXDX (n = 31)	AXDX + RTN (n = 33)	P Value
LOS
Hospital LOS	10.3 (6.2–18.2)	9.5 (5.9–20.1)	7.9 (6.1–13.6)	.567	7.2 (4.8–11.3)	5.5 (3.3–8.9)^a	4.5 (2.9–9.7)^a	.003	7.7 (4.4–15.0)	3.8 (3.1–7.0)^{a, b}	8.0 (4.2–14.1)	.008
Hospital LOS following culture collection	8.3 (5.9–11.0)	7.5 (5.1–14.0)	7.3 (5.7–11.2)	.813	6.1 (4.1–8.6)	4.8 (3.0–7.7)^a	4.2 (2.9–7.3)^a	.026	6.8 (4.4–10.5)	3.8 (3.0–6.9)^a	5.5 (4.0–10.8)	.014
ICU LOS	4.7 (2.0–10.7)	6.0 (1.6–9.4)	4.5 (3.1–6.7)	.866	2.0 (0.9–3.7)	2.6 (1.4–4.1)	2.1 (1.4–3.2)	.313	2.8 (1.6–6.5)	1.9 (1.4–5.0)	2.8 (1.6–4.0)	.864
ICU LOS following culture collection	3.5 (1.7–6.2)	3.0 (4.6–9.4)	4.7 (3.1–5.5)	.728	1.6 (0.9–3.5)	2.2 (1.3–4.0)	2.0 (1.0–2.9)	.606	2.7 (1.6–3.8)	1.9 (1.4–5.0)	2.8 (1.6–4.0)	.898
Optimal therapy
Achieved optimal therapy, No. (%)	51 (94.4)	43 (93.5)	36 (100.0)	.317	62 (78.5)	71 (94.7)^a	71 (93.4)^a	.002	42 (82.0)	28 (90.3)	31 (93.9)	.238
TTOT following culture collection	2.8 (1.9–3.4)	1.8 (0.8–2.8)^a	1.5 (1.1–1.9)^a	≤ .001	2.9 (0.5–3.5)	1.3 (0.0–2.3)^a	1.0 (0.0–2.0)^a	≤ .001	3.2 (2.2–3.9)	1.4 (0.5–2.0)^a	1.5 (1.0–2.1)^a	≤ .001
CDI within 90 d, No. (%)	2 (3.7)	1 (2.2)	3 (8.3)	.385	1 (1.3)	4 (5.3)	5 (6.6)	.237	2 (4.0)	3 (9.7)	4 (12.1)	.373
In-hospital transition to hospice care, No. (%)	4 (7.4)	7 (15.2)	2 (5.6)	.267	6 (7.6)	4 (5.3)	4 (5.3)	.788	2 (4.0)	4 (12.9)	2 (6.1)	.306
In-hospital mortality, No. (%)	5 (9.3)	7 (15.2)	2 (5.6)	.345	6 (7.6)	2 (2.7)	4 (5.3)	.390	4 (8.0)	2 (6.5)	4 (12.1)	.704
Antibiotic use
Total antibiotic use	8 (7–12)	9 (6–14)	8 (6–12)	.913	6 (4–9)	5 (2–7)	4 (3–7)	.060	8 (5–11)	5 (4–8)^a,b	6 (5–12)	.007
BGP	4 (2–7)	5 (2–9)	4 (2–7)	.845	4 (2–6)	3 (1–6)^a	2 (1–4)^a	.003	2 (0–4)	2 (1–3)	1 (0–4)	.719
Vancomycin	3 (2–6)	4 (2–9)	4 (2–7)	.997	5 (3–7)	3 (2–7)	3 (2–4)^a	.002	2 (1–4)	2 (1–3)	2 (1–6)	.438
BGN	4 (2–6)	4 (1–6)	3 (2–5)	.636	4 (1–7)	2 (0–7)	3 (0–5)^a	.046	7 (4–10)	4 (2–7)^a	5 (2–8)^a	.028
NBL	3 (0–8)	4 (0–6)	4 (1–7)	.749	0 (0–1)	0 (0–2)^a	0 (0–2)^a	.010	1 (0–4)	0 (0–2) ^b	3 (2–5)^a	.001

	Gram-Positive Cocci Bacteremia (Excluding CoNS)				CoNS Bacteremia				Gram-Negative Rod Bacteremia
Outcome and Antibiotic Use	Historical (n = 54)	AXDX (n = 46)	AXDX + RTN (n = 36)	P Value	Historical (n = 79)	AXDX (n = 75)	AXDX + RTN (n = 76)	P Value	Historical (n = 50)	AXDX (n = 31)	AXDX + RTN (n = 33)	P Value
LOS
Hospital LOS	10.3 (6.2–18.2)	9.5 (5.9–20.1)	7.9 (6.1–13.6)	.567	7.2 (4.8–11.3)	5.5 (3.3–8.9)^a	4.5 (2.9–9.7)^a	.003	7.7 (4.4–15.0)	3.8 (3.1–7.0)^{a, b}	8.0 (4.2–14.1)	.008
Hospital LOS following culture collection	8.3 (5.9–11.0)	7.5 (5.1–14.0)	7.3 (5.7–11.2)	.813	6.1 (4.1–8.6)	4.8 (3.0–7.7)^a	4.2 (2.9–7.3)^a	.026	6.8 (4.4–10.5)	3.8 (3.0–6.9)^a	5.5 (4.0–10.8)	.014
ICU LOS	4.7 (2.0–10.7)	6.0 (1.6–9.4)	4.5 (3.1–6.7)	.866	2.0 (0.9–3.7)	2.6 (1.4–4.1)	2.1 (1.4–3.2)	.313	2.8 (1.6–6.5)	1.9 (1.4–5.0)	2.8 (1.6–4.0)	.864
ICU LOS following culture collection	3.5 (1.7–6.2)	3.0 (4.6–9.4)	4.7 (3.1–5.5)	.728	1.6 (0.9–3.5)	2.2 (1.3–4.0)	2.0 (1.0–2.9)	.606	2.7 (1.6–3.8)	1.9 (1.4–5.0)	2.8 (1.6–4.0)	.898
Optimal therapy
Achieved optimal therapy, No. (%)	51 (94.4)	43 (93.5)	36 (100.0)	.317	62 (78.5)	71 (94.7)^a	71 (93.4)^a	.002	42 (82.0)	28 (90.3)	31 (93.9)	.238
TTOT following culture collection	2.8 (1.9–3.4)	1.8 (0.8–2.8)^a	1.5 (1.1–1.9)^a	≤ .001	2.9 (0.5–3.5)	1.3 (0.0–2.3)^a	1.0 (0.0–2.0)^a	≤ .001	3.2 (2.2–3.9)	1.4 (0.5–2.0)^a	1.5 (1.0–2.1)^a	≤ .001
CDI within 90 d, No. (%)	2 (3.7)	1 (2.2)	3 (8.3)	.385	1 (1.3)	4 (5.3)	5 (6.6)	.237	2 (4.0)	3 (9.7)	4 (12.1)	.373
In-hospital transition to hospice care, No. (%)	4 (7.4)	7 (15.2)	2 (5.6)	.267	6 (7.6)	4 (5.3)	4 (5.3)	.788	2 (4.0)	4 (12.9)	2 (6.1)	.306
In-hospital mortality, No. (%)	5 (9.3)	7 (15.2)	2 (5.6)	.345	6 (7.6)	2 (2.7)	4 (5.3)	.390	4 (8.0)	2 (6.5)	4 (12.1)	.704
Antibiotic use
Total antibiotic use	8 (7–12)	9 (6–14)	8 (6–12)	.913	6 (4–9)	5 (2–7)	4 (3–7)	.060	8 (5–11)	5 (4–8)^a,b	6 (5–12)	.007
BGP	4 (2–7)	5 (2–9)	4 (2–7)	.845	4 (2–6)	3 (1–6)^a	2 (1–4)^a	.003	2 (0–4)	2 (1–3)	1 (0–4)	.719
Vancomycin	3 (2–6)	4 (2–9)	4 (2–7)	.997	5 (3–7)	3 (2–7)	3 (2–4)^a	.002	2 (1–4)	2 (1–3)	2 (1–6)	.438
BGN	4 (2–6)	4 (1–6)	3 (2–5)	.636	4 (1–7)	2 (0–7)	3 (0–5)^a	.046	7 (4–10)	4 (2–7)^a	5 (2–8)^a	.028
NBL	3 (0–8)	4 (0–6)	4 (1–7)	.749	0 (0–1)	0 (0–2)^a	0 (0–2)^a	.010	1 (0–4)	0 (0–2) ^b	3 (2–5)^a	.001

Data presented as median days (interquartile range) unless otherwise indicated. Statistically significant values are highlighted in bold (P ≤ .05). The Candida subgroup analysis was not included due to low incidence.

Abbreviations: AXDX, Accelerate Pheno system; BGN, broad gram negative; BGP, broad gram positive; CDI, Clostridioides difficile infection; CoNS, coagulase-negative staphylococci; ICU, intensive care unit; LOS, length of stay; NBL, narrow β-lactam; RTN, real-time notification; TTOT, time to optimal therapy.

^aStatistically significant (P ≤ .05) compared to historical cohort.

^bStatistically significant (P ≤ .05) compared to the AXDX-RTN cohort.

This Feature Is Available To Subscribers Only